Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Director James N. Topper of NewAmsterdam Pharma Co N.V. (NASDAQ:NAMS), a $2.1 billion market cap pharmaceutical company, recently purchased shares of the company’s stock. On June 24, 2025, Topper acquired 2,520 shares at a weighted average price of $18.4343, in multiple transactions at prices ranging from $18.305 to $18.63, for a total value of $46,454. Then, on June 25, 2025, Topper acquired 1,260 shares at a weighted average price of $18.2632, in multiple transactions at prices ranging from $18.10 to $18.3795, for a total value of $22,992. According to InvestingPro data, the company maintains strong financial health with a current ratio of 19.98x, indicating robust liquidity.
Following these transactions, Topper directly holds 3,026,133 shares through Frazier Life Sciences X, L.P., and 3,801,000 shares through Frazier Lifesciences Sponsor LLC. Analysts maintain a strong buy consensus on NAMS, with price targets ranging from $37.72 to $53.01. For deeper insights into insider trading patterns and comprehensive analysis, check out the detailed Pro Research Report available on InvestingPro.
In other recent news, NewAmsterdam Pharma announced positive results from a sub-study of its Phase 3 BROADWAY trial, highlighting significant reductions in Alzheimer’s disease biomarkers. The trial primarily focused on assessing obicetrapib’s efficacy in lowering low-density lipoprotein cholesterol (LDL-C) in patients with cardiovascular conditions. Statistically significant reductions in Alzheimer’s biomarker p-tau217 were observed, especially in patients carrying the ApoE4 gene variant. On the financial front, Citi initiated coverage of NewAmsterdam Pharma with a buy rating, citing the potential of obicetrapib in the cholesterol-lowering market. Cantor Fitzgerald and Stifel both maintained positive outlooks on the company, with Stifel setting a $44 price target and highlighting the drug’s potential in the expanding lipid-lowering market. Stifel’s analysis also emphasized NewAmsterdam’s strong financial position and the promising outlook for obicetrapib in the PREVAIL trial. Additionally, the company shared market research suggesting a potential $8 billion worldwide opportunity for obicetrapib, though Stifel maintains a more conservative estimate of approximately $4.5 billion. These developments underscore NewAmsterdam Pharma’s strategic positioning in the pharmaceutical industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.